The earnings call reflects a positive outlook with significant advancements in regulatory approvals, strategic collaborations, and commercial readiness efforts. While there are challenges related to financial constraints and dependencies on partnerships, the company's progress and strategic planning position it well for future commercialization and growth.

Company Guidance -

Q2 2025

During the HeartBeam First Quarter 2025 Financial Results Conference Call, CEO Rob Eno and CFO Tim Cruickshank provided guidance on the company's progress and future plans. Key metrics discussed included the achievement of several milestones, such as the presentation of the VALID-ECG study results, which showed a high level of agreement (93.4%) between synthesized and standard 12-lead ECGs for arrhythmia assessment. The company anticipates FDA clearance for their 12-lead synthesis software by the end of the year, vital for their commercial launch. They also reported financial discipline, with $4.5 million used in operating activities in Q1, and completed an $11.5 million common stock public offering. HeartBeam plans to focus on securing FDA clearance and commercial readiness, targeting a $500 million U.S. market with a projected $50-$100 monthly revenue per patient. They are preparing for a commercial launch expected by the end of 2025, with infrastructure and strategic collaborations, such as with AccurKardia, enhancing their competitive positioning.

FDA 510(k) Clearance and Progress

HeartBeam received foundational FDA 510(k) clearance for its system, including arrhythmia assessment. They are in positive discussions with the FDA for the 12-lead synthesis software and anticipate clearance by the end of the year.

VALID-ECG Study Success

The VALID-ECG study met its endpoint, supporting the FDA submission for the 12-lead synthesis software. The study showed a 93.4% agreement with standard 12-lead ECGs, demonstrating the effectiveness of HeartBeam's technology.

AccurKardia Collaboration

HeartBeam announced a strategic collaboration with AccurKardia to integrate FDA-cleared ECG algorithms, enhancing their commercial product and reducing time and expenses associated with developing their own solution.

Intellectual Property Expansion

HeartBeam has added two new issued U.S. patents, bringing the total to 20 worldwide, strengthening their proprietary technology position.

Commercial Readiness and Early Access Program

HeartBeam is progressing well towards commercial readiness, including testing with concierge accounts and patients, and has established a contract manufacturer for scaling.

Successful Fundraising

HeartBeam completed an $11.5 million common stock public offering, supporting their strategic funding approach and commercialization efforts.

HeartBeam (BEAT) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

BEAT Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Aug 13, 2025	2025 (Q2)	-0.18 / -	-0.19	―	―	―
May 13, 2025	2025 (Q1)	-0.15 / -0.18	-0.17	-5.88% (>-0.01)
Mar 13, 2025	2024 (Q4)	-0.19 / -0.18	0.07	-357.14% (-0.25)
Nov 07, 2024	2024 (Q3)	-0.17 / -0.19	-0.13	-46.15% (-0.06)
Aug 14, 2024	2024 (Q2)	-0.17 / -0.19	-0.16	-18.75% (-0.03)
May 09, 2024	2024 (Q1)	-0.15 / -0.17	-0.5	66.00% (+0.33)
Mar 20, 2024	2023 (Q4)	-0.12 / 0.07	-0.45	115.56% (+0.52)
Nov 14, 2023	2023 (Q3)	-0.11 / -0.13	-0.44	70.45% (+0.31)
Aug 10, 2023	2023 (Q2)	-0.23 / -0.16	-0.43	62.79% (+0.27)
May 11, 2023	2023 (Q1)	-0.47 / -0.50	-0.27	-85.19% (-0.23)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

BEAT Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
May 13, 2025	$1.71	$1.60	-6.43%
Mar 13, 2025	$2.02	$2.05	+1.49%
Nov 07, 2024	$2.33	$2.57	+10.30%
Aug 14, 2024	$2.27	$2.31	+1.76%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does HeartBeam (BEAT) report earnings?

HeartBeam (BEAT) is schdueled to report earning on Aug 13, 2025, After Close (Confirmed).

What is HeartBeam (BEAT) earnings time?

HeartBeam (BEAT) earnings time is at Aug 13, 2025, After Close (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is BEAT EPS forecast?

BEAT EPS forecast for the fiscal quarter 2025 (Q2) is -0.18.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing